Business
NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Completed a technology transfer, submitted a new manufacturing file to the United States ("U.S.") Food and Drug Administration ("FDA"), and released new drug
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Completed a technology transfer, submitted a new manufacturing file to the United States (\"U.S.\") Food and Drug Administration (\"FDA\"), and released new drug produced with processes designed to support commercial-stage manufacturing of a Phase 3 investigational drugOn track to report data from ongoing Phase 2 clinical trial of NRX-101 in patients with bipolar depression with sub-acute suicidal ideation and behavior (SSIB) in 1Q 2023Company has received numerous partnering inquiries for NRX-101Plan to initiate registrational Phase 3 clinical trial of NRX-101 in patients with bipolar depression with acute suicidal ideation and behavior (ASIB) by year-end; data readout expected in 3Q 2023Commenced Phase 2 clinical trial planning of NRX-101 for post-traumatic stress disorder (\"PTSD\")Ended quarter with $18.2 million in cash and cash equivalents and announced completion of a subsequent unsecured debt financing on November 7, 2022, providing net proceeds of $10.0 million to support the NRx Pharmaceuticals' pipeline of life-saving therapeuticsRADNOR, Pa., Nov. 14, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", the \"Company\"), a clinical-stage biopharmaceutical company, today announced its financial results for the third quarter of 2022 and provided a business and clinical update.\n\n \n \n \n \n \n \n\n \nNRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update\"In recent months, NRx Pharmaceuticals has made substantial progress advancing our clinical development plans for our lead investigational compound, NRX-101, in multiple psychiatric indications,\" said Stephen Willard, J.D., Chief Executive Officer and Director of NRx Pharmaceuticals. \"Today, someone in the U.S. someone attempts suicide every 27 seconds, and someone dies of suicide every 11 minutes and there is no approved medication for suicidal bipolar depression or PTSD. The only FDA-approved treatment for suicidal bipolar depression remains electroshock therapy. The FDA has granted NRX-101 a Breakthrough Therapy Designation with an accompanying Special Protocol Agreement for treatment of patients with bipolar depression and acute suicidality. If approved, we aim to offer this potentially transformative medicine to patients in 2024. During this exciting time at NRx Pharmaceuticals, we remain...